Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Noonan Syndrome

Other

Noonan Syndrome (NS) Clinical Trials and Treatments

Also called NS, RASopathy, male Turner syndrome

Noonan syndrome (NS) is an autosomal dominant disorder caused by mutations in genes regulating the RAS/MAPK signaling pathway (PTPN11 accounting for ~50% of cases, SOS1, RAF1, RIT1, BRAF, KRAS, and others), making it a primary RASopathy. The condition is characterized by distinctive craniofacial features including hypertelorism (widely spaced eyes), short philtrum, micrognathia (small jaw), and low-set, posteriorly rotated ears.

In plain words, Noonan syndrome is a genetic condition caused by changes in genes that pass signals inside the body's cells. People with it may have distinctive facial features, short height and heart problems, though this varies a lot from person to person.

Get an email when new Noonan Syndrome trials open or the FDA decides. Get alerts

Noonan Syndrome

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 12 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines2

Norditropin · Sogroya

Noonan Syndrome has 2 FDA-approved medicines, 15 open or active clinical trials (13 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Noonan Syndrome

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Noonan Syndrome

Noonan syndrome (NS) is an autosomal dominant disorder caused by mutations in genes regulating the RAS/MAPK signaling pathway (PTPN11 accounting for ~50% of cases, SOS1, RAF1, RIT1, BRAF, KRAS, and others), making it a primary RASopathy.

Keep reading about Noonan Syndrome

The condition is characterized by distinctive craniofacial features including hypertelorism (widely spaced eyes), short philtrum, micrognathia (small jaw), and low-set, posteriorly rotated ears. Short stature affects about 50-70% of patients, who are usually a normal size at birth and grow more slowly over time; response to growth hormone varies.

Cardiac involvement (~80% of patients) includes pulmonary stenosis (most common), hypertrophic cardiomyopathy, atrial septal defect, and aortic stenosis. Developmental delays and learning disabilities occur in 25-75% of patients depending on the causative gene and mutation severity.

Hematologic abnormalities including platelet dysfunction, bleeding tendency, and elevated INR occur in ~50%. Increased cancer predisposition, particularly childhood leukemia and certain solid tumors, requires ongoing surveillance. Prognosis is generally good with appropriate multidisciplinary care; life expectancy is near-normal.

What are the symptoms of Noonan Syndrome?

These are common symptoms of Noonan Syndrome, and how strong they are varies from person to person.

  • Characteristic facial features (hypertelorism, low-set ears, micrognathia)
  • Short stature
  • Cardiac defects (pulmonary stenosis, hypertrophic cardiomyopathy)
  • Developmental and learning delays
  • Bleeding tendency and platelet dysfunction
  • Increased cancer predisposition (particularly leukemia)

Who gets Noonan Syndrome?

NS shows autosomal dominant inheritance. A causative gene change is found in about 80-85% of patients, and the cause is still unknown in 15-20%. The condition affects males and females equally. Approximately 50% of cases are inherited from an affected parent (vertical transmission), while approximately 50% represent new (de novo) mutations. Penetrance is high but variable expressivity is notable, even within the same family.

Geographic and ethnic distribution is worldwide with no significant population predilection. Advanced paternal age increases risk of de novo mutations, particularly PTPN11 mutations. Recurrence risk for offspring of affected individuals is 50% per pregnancy (assuming single-gene inheritance).

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Noonan Syndrome?

There are currently 2 FDA-approved medications for Noonan Syndrome.

somatropin
Novo Nordisk
Search
Sogroya
somapacitan-beco
Novo Nordisk
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Noonan Syndrome treatment

Charity funds and drugmaker programs for Noonan Syndrome, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Noonan Syndrome

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Noonan Syndrome resources

Reputable organizations and medical references for learning more about Noonan Syndrome, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Noonan Syndrome

Use this Noonan Syndrome clinical trial finder to see the 13 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 4 test a treatment and 11 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

15 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT07221851

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Intervention: Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector

Sponsor: Ascendis Pharma A/S

This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and <18 years with open growth plates. The purpose of the study is to see how well treatment with once...

Ages 2 Years to 17 Years
Started Dec 2025Updated 1 week agoEst. Feb 2028 (~1y 3m)
RecruitingObservational study, no treatment givenRecently updatedNCT06147414

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Intervention: Blood sample

Sponsor: Assistance Publique - Hôpitaux de Paris

Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnos...

Ages 18 Years+1 location
Started Oct 2024Updated 4 weeks agoEst. May 2027 (~6 months)
RecruitingObservational study, no treatment givenRecently updatedNCT07881081

Neuroradiological Features of Noonan Syndrome and Genotype-Phenotype Correlations

Intervention: Brain MRI and MR angiography (MRA)

Sponsor: Istituto Giannina Gaslini

Retrospective and prospective collection of brain and spinal MRI and MR angiography images from patients of all ages with a genetically confirmed diagnosis of Noonan syndrome.

Ages not specified
Started May 2021Updated 1 month agoEst. Dec 2026 (~1 month)
RecruitingObservational study, no treatment givenRecently updatedNCT07881159

Registro Nazionale Sindrome Noonan / National Registry of Noonan Syndrome

Sponsor: Istituto Giannina Gaslini

This study will create a national registry (a secure online database) of people with Noonan syndrome in Italy. Noonan syndrome is a genetic condition. It can affect growth, the heart, and other parts of the body. It is rare, so doctors have limited information about how it develops over time.

Ages not specified
Started Oct 2022Updated 1 month agoEst. Dec 2027 (~1y 1m)
RecruitingTreatment trialRecently updatedNCT05361811

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

Intervention: Waitlist, ACT Intervention

Sponsor: National Cancer Institute (NCI)

Background:

Ages 18 Years+1 location
Started Jan 2024Updated 1 month agoEst. Jun 2027 (~6 months)
Find Noonan Syndrome trials near you, ranked by distance →
Active trial locations29 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+21 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Noonan Syndrome trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Noonan Syndrome foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Noonan Syndrome patient communities

Facebook groups, Reddit communities and YouTube channels where Noonan Syndrome patients, caregivers and advocacy groups talk.

Companies developing Noonan Syndrome treatments

Drugmakers that list Noonan Syndrome in their rare disease portfolio, 2 in all.

Questions people ask about Noonan Syndrome